Drugs / Dorzolamide-timolol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2/3 | NCT03034772 Comparator | Feb 2017 → Feb 2019 | wet macular degeneration | Wills Eye | Completed | No outcome recorded |
| Phase 4 | NCT00822055 Comparator | May 2005 → Nov 2006 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| — | NCT01257698 Comparator | Feb 2010 → Jun 2013 | macular holes, retinal detachment | Mid Atlantic Retina | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dorzolamide-timolol | “topical brimonidine-timolol BID or dorzolamide-timolol BID as monotherapy” PMID 19476406 ↗ Jul 2009 |
| Route | Topical | “received topical brimonidine-timolol BID or dorzolamide-timolol BID” PMID 19476406 ↗ Jul 2009 |